Shah Nirmal, Patel Priyank, Gohil Dipti, Maheshwari Rajesh, Talele Chitrali, Talele Dipali, Parikh Dhaivat, Patwa Jay
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, India.
Pharmacy and Healthcare, Cape Breton University, Sydney, Canada.
Pharm Dev Technol. 2025 Jul;30(6):863-874. doi: 10.1080/10837450.2025.2525256. Epub 2025 Jun 30.
Leflunomide, a frequently used medicament, falls under the category of disease modifying anti-rheumatoid drugs. The tablets are the only product available in the market which may lead to liver toxicity upon long-term use. Being a class II drug, there is a need of some novel formulation for minimizing systemic toxicity of drug without compromising its therapeutic potential. Microsponges possess unique characteristics that makes it a versatile drug delivery carrier. Leflunomide loaded Microsponges were prepared with matrix forming polymer (ethyl cellulose) and stabilizer (poly vinyl alcohol) using quasi-emulsion solvent diffusion method. Two independent parameters, namely concentrations of polymer and stabilizing agent, were examined using a full 3 factorial design to determine their impact on particle size and % entrapment efficiency. The optimized formulation showed promising result for particle size (48.96 µm) and entrapment efficiency (89.45%) with spherical and tiny pores on surface. The optimized gel exhibited sustained release up to 8 h (91.46 ± 3.84%) with satisfactory results of flux and permeability coefficient. The developed formulation has good anti-inflammatory properties in wistar rats and a histopathology investigation on rats' skin verified its skin compatibility. The stability study showed stable formulation up to the period of 3 months. These findings demonstrated the potential of microsponges to improve the therapeutic potential of poorly soluble leflunomide.
来氟米特是一种常用药物,属于改善病情抗风湿药。该片剂是市场上唯一长期使用可能导致肝毒性的产品。作为二类药物,需要一些新型制剂来在不损害其治疗潜力的情况下将药物的全身毒性降至最低。微球具有独特的特性,使其成为一种多功能药物递送载体。采用准乳液溶剂扩散法,用基质形成聚合物(乙基纤维素)和稳定剂(聚乙烯醇)制备了载来氟米特微球。使用全3因子设计研究了两个独立参数,即聚合物浓度和稳定剂浓度,以确定它们对粒径和包封率的影响。优化后的制剂在粒径(48.96 µm)和包封率(89.45%)方面显示出良好的结果,表面具有球形和微小孔隙。优化后的凝胶可持续释放8小时(91.46±3.84%),通量和渗透系数结果令人满意。所开发的制剂在Wistar大鼠中具有良好的抗炎特性,对大鼠皮肤的组织病理学研究证实了其皮肤相容性。稳定性研究表明,该制剂在3个月内稳定。这些发现证明了微球在提高难溶性来氟米特治疗潜力方面的潜力。